Scholarlink

Background <p>The global decline in the efficacy of empirical treatment for <i>Helicobacter pylori</i> eradication driven largely by rising antibiotic resistance has prompted increasing interest in tailored therapeutic approaches. Tailored therapy, guided by antimicrobial susceptibility testing (AST), offers a theoretically superior strategy by enabling selection of effective, resistance-informed regimens. However, the comparative effectiveness of tailored versus empirical therapy remains uncertain across different clinical contexts and geographic regions.</p> Materials and methods <p>This systematic review was conducted in accordance with PRISMA 2020 guidelines. A comprehensive search of PubMed, Embase, Web of Science, and CENTRAL was performed to identify studies published inception to August 2025 that directly compared empirical and AST-guided tailored therapy for <i>H. pylori</i> eradication. Eligible studies included randomized controlled trials and observational comparative studies reporting intention-to-treat or per-protocol eradication rates. Study selection, data extraction, and risk-of-bias assessments (Newcastle-Ottawa Scale) were performed independently by two reviewers.</p> Results <p>Fifty-five studies comprising approximately 14,940 patients were included. Tailored therapy demonstrated higher eradication rates in 85% of first-line studies, with PCR-guided regimens achieving the most consistent success. In rescue settings, tailored therapy showed variable outcomes, with several studies reporting comparable efficacy to empirical quadruple therapy. Overall, tailored regimens were more effective in high-resistance settings and when guided by timely and accurate AST.</p> Conclusion <p>The summarized evidence suggests that tailored therapy, guided by antimicrobial susceptibility testing, often achieves higher <i>H. pylori</i> eradication rates than empirical therapy, especially as a first-line approach. However, the heterogeneity in study design and outcomes necessitates careful consideration when applying these findings. Tailored therapy appears to be a valuable strategy to optimize <i>H. pylori</i> eradication, potentially combating rising antibiotic resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Hamidreza Zivarifar,
  • Masoud Keikha

摘要

Background

The global decline in the efficacy of empirical treatment for Helicobacter pylori eradication driven largely by rising antibiotic resistance has prompted increasing interest in tailored therapeutic approaches. Tailored therapy, guided by antimicrobial susceptibility testing (AST), offers a theoretically superior strategy by enabling selection of effective, resistance-informed regimens. However, the comparative effectiveness of tailored versus empirical therapy remains uncertain across different clinical contexts and geographic regions.

Materials and methods

This systematic review was conducted in accordance with PRISMA 2020 guidelines. A comprehensive search of PubMed, Embase, Web of Science, and CENTRAL was performed to identify studies published inception to August 2025 that directly compared empirical and AST-guided tailored therapy for H. pylori eradication. Eligible studies included randomized controlled trials and observational comparative studies reporting intention-to-treat or per-protocol eradication rates. Study selection, data extraction, and risk-of-bias assessments (Newcastle-Ottawa Scale) were performed independently by two reviewers.

Results

Fifty-five studies comprising approximately 14,940 patients were included. Tailored therapy demonstrated higher eradication rates in 85% of first-line studies, with PCR-guided regimens achieving the most consistent success. In rescue settings, tailored therapy showed variable outcomes, with several studies reporting comparable efficacy to empirical quadruple therapy. Overall, tailored regimens were more effective in high-resistance settings and when guided by timely and accurate AST.

Conclusion

The summarized evidence suggests that tailored therapy, guided by antimicrobial susceptibility testing, often achieves higher H. pylori eradication rates than empirical therapy, especially as a first-line approach. However, the heterogeneity in study design and outcomes necessitates careful consideration when applying these findings. Tailored therapy appears to be a valuable strategy to optimize H. pylori eradication, potentially combating rising antibiotic resistance.